Variable | Time | CoQ10 | Placebo | Significance | |
---|---|---|---|---|---|
Superoxide Dismutase (SOD) (U/ml) | Baseline T2 | 1.52 ± 0.31 | 1.59 ± 0.27 | Group | 0.103 |
 | Isokinetic T2 | 1.56 ± 0.24 | 1.80 ± 0.39 | Time | 0.001 |
 | Wingate T2 | 1.75 ± 0.23 | 1.70 ± 0.22 | G × T | 0.060 |
 | GXT T2 | 1.68 ± 0.17 | 1.70 ± 0.26 |  |  |
 | Baseline T3 | 1.61 ± 0.40 | 1.77 ± 0.52 | Group | 0.296 |
 | Isokinetic T3 | 1.74 ± 0.37 | 1.90 ± 0.54 | Time | 0.001†|
 | Wingate T3 | 1.91 ± 0.39 | 2.06 ± 0.51 | G × T | 0.966 |
 | GXT T3 | 1.81 ± 0.42 | 1.98 ± 0.50 |  |  |
Thiobarbituric Acid Reactive Substance (TBARS) (μM) | Baseline T2 | 2.79 ± 1.02 | 2.50 ± 1.34 | Group | 0.042 |
 | Isokinetic T2 | 4.11 ± 1.71 | 3.24 ± 1.69 | Time | 0.001 |
 | Wingate T2 | 4.72 ± 2.14 | 3.35 ± 1.57†| G × T | 0.018†|
 | GXT T2 | 5.09 ± 2.23 | 3.62 ± 1.90†|  |  |
 | Baseline T3 | 3.03 ± 1.03 | 3.12 ± 1.26 | Group | 0.540 |
 | Isokinetic T3 | 4.28 ± 1.72 | 4.23 ± 1.47 | Time | 0.001 |
 | Wingate T3 | 4.25 ± 1.17 | 4.85 ± 2.11 | G × T | 0.534 |
 | GXT T3 | 5.32 ± 2.09 | 5.52 ± 1.89 |  |  |
8-Isoprostane (pg/ml) | Baseline T2 | 76 ± 28 | 78 ± 33 | Group | 0.616 |
 | Isokinetic T2 | 86 ± 63 | 88 ± 61 | Time | 0.050 |
 | Wingate T2 | 105 ± 72 | 99 ± 63 | G × T | 0.431 |
 | GXT T2 | 108 ± 67 | 110 ± 62 |  |  |
 | Baseline T3 | 84 ± 46 | 79 ± 35 | Group | 0.334 |
 | Isokinetic T3 | 101 ± 37 | 124 ± 75 | Time | 0.001 |
 | Wingate T3 | 114 ± 53 | 122 ± 69 | G × T | 0.553 |
 | GXT T3 | 99 ± 49 | 111 ± 87 |  |  |